Atomo Diagnostics Ltd (ASX: AT1) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Atomo Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $12.14 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 639.20 million
Earnings per share -0.010
Dividend per share N/A
Year To Date Return N/A
Earnings Yield N/A
Franking -
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

Atomo Diagnostics Ltd (ASX: AT1)
Latest News

Doctor doing a telemedicine using laptop at a medical clinic
Share Gainers

Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!

Investors are bidding up the ASX healthcare stock amid extra funding in the Federal budget.

Read more »

Two happy scientists analysing test results.
Share Gainers

Guess which ASX pharmaceutical stock just rocketed 122%!

Investors are piling into the ASX pharmaceutical stock on Wednesday.

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development
Healthcare Shares

3 ASX healthcare shares rocketing 20% to 100% today

These ASX shares are thumping the market on Tuesday and making their shareholders smile.

Read more »

laboratory workers looking disappointed
Earnings Results

3 ASX healthcare shares punished following full-year results

It wasn't so rosy for all those reporting earnings today

Read more »

a woman winces as she inserts a home diagnostic test for COVID-19 up her nose with her sofa in the background.
Earnings Results

Negative result: Atomo Diagnostics (ASX: AT1) shares plunge 18% on half-year earnings

What did the diagnostics report in its results?

Read more »

A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
Coronavirus News

Why are ASX COVID test shares climbing today?

COVID-19 tests are in focus again today.

Read more »

Health workers shake hands and congratulate each other on good news.
Healthcare Shares

Here's why the Atomo (ASX:AT1) share price is rocketing 17% today

Atomo is cementing its presence across key markets.

Read more »

female nurse in scrubs
Healthcare Shares

Why has the Atomo Diagnostics (ASX: AT1) share price surged 50% since Christmas?

Could this be why the company's stock has taken off lately?

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Why is the Atomo Diagnostics (ASX:AT1) share price wobbling on Thursday?

It's been a busy week so far for the medical devices company

Read more »

Woman prepares to insert a swab in her nose to test for COVID-19 at home.
Healthcare Shares

Is AM Diagnostics listed on the ASX?

The supplier of Australia's only approved at-home COVID-19 tests is the talk of the ASX today.

Read more »

share price dropping
Share Fallers

Why Afterpay, Atomo, Opthea, & Sealink shares are falling today

These ASX shares are in the red on Tuesday...

Read more »

ASX shares downgrade A young woman with tattoos puts both thumbs down and scrunches her face with the bad news.
Share Market News

Here's why the Atomo (ASX:AT1) share price is crashing 9% today

This ASX share is having a bad start to the week...

Read more »

AT1 ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Atomo Diagnostics Ltd

Atomo Diagnostics Limited is a medical device company. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions

AT1 Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
24 Apr 2025 $0.02 $0.00 0.00% 883,724 $0.02 $0.02 $0.02
16 Apr 2025 $0.02 $0.00 0.00% 46,400 $0.02 $0.02 $0.02
15 Apr 2025 $0.02 $0.00 0.00% 1,935,640 $0.02 $0.02 $0.02
14 Apr 2025 $0.02 $0.00 0.00% 3,813,005 $0.02 $0.02 $0.02
11 Apr 2025 $0.02 $0.00 0.00% 4,739 $0.02 $0.02 $0.02
10 Apr 2025 $0.02 $0.00 0.00% 650,000 $0.02 $0.02 $0.02
09 Apr 2025 $0.02 $0.00 0.00% 949,217 $0.02 $0.02 $0.02
08 Apr 2025 $0.02 $0.00 0.00% 2,053,314 $0.02 $0.02 $0.02
07 Apr 2025 $0.02 $0.00 0.00% 1,859,024 $0.02 $0.02 $0.02
04 Apr 2025 $0.02 $0.00 0.00% 570,997 $0.02 $0.02 $0.02
03 Apr 2025 $0.02 $0.00 0.00% 4,831 $0.02 $0.02 $0.02
01 Apr 2025 $0.02 $0.00 0.00% 3,000 $0.02 $0.02 $0.02
31 Mar 2025 $0.02 $0.00 0.00% 552,941 $0.02 $0.02 $0.02
28 Mar 2025 $0.02 $0.00 0.00% 78,573 $0.02 $0.02 $0.02
27 Mar 2025 $0.02 $0.00 0.00% 296,024 $0.02 $0.02 $0.02
26 Mar 2025 $0.02 $0.00 0.00% 1,319 $0.02 $0.02 $0.02

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Paul Alexander Kasian Non-Executive Director
Dr Kasian is an executive director with demonstrated achievement in both domestic and international companies encompassing senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. He is also Chair of Risk Committee and member of the People and Culture Committee.
Mr John Perry Keith Non-Executive ChairmanNon-Executive Director Dec 2011
Mr Keith is one of the Managing Directors at BNP Paribas, establishing and leading its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign, and institutional clients across all areas of investment and institutional banking. He is Member of the Risk Committee and member of the People and Culture Committee.
Mr John Michael Kelly FounderChief Executive OfficerManaging Director Apr 2010
Mr Kelly has focused on developing and commercializing innovative healthcare products that enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the Mirage Swift and Activa mask systems.
Ms Deborah Neff Non-Executive Director Sep 2021
Ms Neff has spent most of her career building global businesses. As principal of DJN Consulting, LLC based in the San Francisco Bay Area, Deborah currently works with several privately held healthcare start-up companies providing strategic business advice and mentoring to the executive management teams. Previously was CEO of Evanostics, LLC, Pathwork Diagnostics Inc, and COO at Complete Genomics following a 15-year career with Becton Dickinson, where she last served as President of BD Biosciences, a global business unit of the company. She is an Executive Trustee of the University of California, Davis Foundation and chairs the College of Biological Sciences Leadership Council at the University. He is also member of the Risk Committee.
Dr Cheri Louise Walker Non-Executive Director Nov 2022
Dr Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Dr. Walker is currently the President, Chief Executive Officer, and Director of Rhinostics. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher. He is a member of the Risk Committee.
Mr Mathew Leslie Watkins Company Secretary Jun 2024
-
Mathew Leslie Watkins Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
GZ Family Holdings Pty Ltd 79,787,536 12.48%
Dalraida Holdings Pty Limited 65,120,000 10.19%
Global Health Investment Fund 64,811,280 10.14%
Mr Xiaoyi Lin 11,880,000 1.86%
Grand Challenges Canada 11,390,824 1.78%
Liverbird Pty Ltd 10,931,653 1.71%
Australia West Holdings Pty 10,500,000 1.64%
Australia North Holdings Pty 9,580,000 1.50%
ID&E Pty Ltd 9,032,248 1.41%
Mark Andrew Smith 7,790,224 1.22%
Mr Ian Fredrick Johnson 7,506,080 1.17%
John Michael Kelly 7,370,248 1.15%
Leo James Lynch 7,321,121 1.15%
Citicorp Nominees Pty Limited 6,355,684 0.99%
Mr Ankur Choudhary 5,887,126 0.92%
Ruth Karen Devney 5,626,408 0.88%
Sokolov Pty Ltd 4,031,888 0.63%
H & L Management Pty Ltd 4,000,000 0.63%
Rue Des Rocs Pty Ltd 3,800,000 0.59%
Miss Lisa Marie Mackenzie 3,351,968 0.52%

Profile

since

Note